Lipigon Pharmaceuticals AB (SE:LPGO)
:LPGO
Top Page
Lipigon Pharmaceuticals AB
(LPGO)
Select Model
Select Model
Rating:43Neutral
Price Target:
kr0.01
▲(10.00% Upside)
Action:ReiteratedDate:04/11/26
The score is driven primarily by weak financial performance (persistent losses, cash burn, and an unstable revenue profile with zero revenue in 2025), partially mitigated by the lack of debt. Technical and valuation inputs are limited, with negative P/E reflecting ongoing losses and insufficient technical indicators to confirm momentum or trend.
Positive Factors
Focused cardiometabolic therapeutic niche
A clear strategic focus on cardiometabolic diseases concentrates R&D resources on a large, persistent clinical need. This specialization supports deeper domain expertise, clearer development milestones, and stronger appeal to partners seeking targeted lipid‑lowering or cardiovascular programs over the medium term.
Negative Factors
Persistent negative cash flow
Sustained operating and free cash outflows indicate ongoing burn without internal cash generation. Over months, this materially increases reliance on external capital, risks asset depletion, and pressures management to raise funds or cut programs, undermining long‑term program continuity.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused cardiometabolic therapeutic niche
A clear strategic focus on cardiometabolic diseases concentrates R&D resources on a large, persistent clinical need. This specialization supports deeper domain expertise, clearer development milestones, and stronger appeal to partners seeking targeted lipid‑lowering or cardiovascular programs over the medium term.
Read all positive factors
Lipigon Pharmaceuticals AB (LPGO) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr3.51M
Dividend YieldN/A
Average Volume (3M)2.79M
Price to Earnings (P/E)―
Beta (1Y)1.14
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.01
Shares Outstanding605,933,700
10 Day Avg. Volume2,063,232
30 Day Avg. Volume2,789,495
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.44
Price to Sales (P/S)0.00
P/FCF Ratio-0.10
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Lipigon Pharmaceuticals AB Business Overview & Revenue Model
Company Description
Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a g...
How the Company Makes Money
As a clinical-stage biotech, Lipigon’s ability to generate recurring product sales revenue is null (no marketed products publicly indicated). Its business model is primarily R&D-driven and typically monetizes value through (1) partnering and licen...
Lipigon Pharmaceuticals AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 10.29M | 16.41M | 390.00K | 3.18M |
| Gross Profit | -83.00K | -26.29M | -5.12M | 366.00K | -36.04M |
| EBITDA | -31.68M | -25.14M | -12.10M | -37.68M | -41.09M |
| Net Income | -32.44M | -25.26M | -12.13M | -37.67M | -41.12M |
Balance Sheet | |||||
| Total Assets | 11.49M | 14.82M | 33.60M | 10.82M | 29.43M |
| Cash, Cash Equivalents and Short-Term Investments | 10.21M | 11.78M | 31.93M | 9.64M | 28.47M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 3.57M | 7.06M | 5.16M | 6.95M | 6.47M |
| Stockholders Equity | 7.91M | 7.76M | 28.45M | 3.87M | 22.96M |
Cash Flow | |||||
| Free Cash Flow | -35.88M | -25.02M | -14.32M | -37.47M | -35.42M |
| Operating Cash Flow | -35.77M | -24.78M | -14.32M | -37.47M | -35.30M |
| Investing Cash Flow | -108.00K | -235.00K | 0.00 | 0.00 | -119.00K |
| Financing Cash Flow | 34.32M | 4.58M | 36.70M | 18.61M | 51.09M |
Lipigon Pharmaceuticals AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:LPGO
Lipigon Pharmaceuticals AB
0.01
-0.09
-88.66%
DE:5KC
PILA PHARMA AB
0.15
-0.08
-34.89%
DE:7UX
Spago Nanomedical AB
0.01
0.00
0.00%
DE:COJ0
CombiGene AB
0.15
<0.01
0.68%
DE:5JA1
Sprint Bioscience AB
0.25
0.21
578.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.